Woodline Partners LP Has $72.54 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Woodline Partners LP trimmed its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 29.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,131,948 shares of the company's stock after selling 2,554,528 shares during the period. Woodline Partners LP owned approximately 0.84% of Roivant Sciences worth $72,541,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. FMR LLC raised its position in Roivant Sciences by 0.3% during the fourth quarter. FMR LLC now owns 49,301,583 shares of the company's stock valued at $583,238,000 after buying an additional 156,527 shares during the period. Vanguard Group Inc. raised its position in Roivant Sciences by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock valued at $521,553,000 after buying an additional 2,404,232 shares during the period. Patient Square Capital LP raised its position in Roivant Sciences by 2.1% during the fourth quarter. Patient Square Capital LP now owns 12,480,000 shares of the company's stock valued at $147,638,000 after buying an additional 251,535 shares during the period. Two Seas Capital LP raised its position in Roivant Sciences by 4.6% during the fourth quarter. Two Seas Capital LP now owns 10,167,807 shares of the company's stock valued at $120,285,000 after buying an additional 442,914 shares during the period. Finally, Invesco Ltd. grew its stake in Roivant Sciences by 49.7% in the fourth quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock valued at $112,563,000 after purchasing an additional 3,159,603 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Roivant Sciences

In other news, major shareholder Vivek Ramaswamy sold 273,959 shares of the company's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the completion of the sale, the insider now owns 39,799,611 shares in the company, valued at approximately $456,501,538.17. This represents a 0.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Eric Venker sold 434,478 shares of the company's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $10.82, for a total value of $4,701,051.96. Following the sale, the chief operating officer now owns 1,127,290 shares of the company's stock, valued at approximately $12,197,277.80. This trade represents a 27.82% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,223,959 shares of company stock worth $13,450,035. 7.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ROIV has been the topic of a number of recent research reports. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Monday, April 21st.

Roivant Sciences Trading Down 0.6%

NASDAQ ROIV traded down $0.07 on Friday, reaching $10.87. The stock had a trading volume of 2,442,270 shares, compared to its average volume of 5,579,306. The business has a 50 day moving average price of $10.53 and a 200 day moving average price of $11.05. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $13.06. The company has a market capitalization of $7.76 billion, a price-to-earnings ratio of -72.46 and a beta of 1.23.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.